NCT06592131View on ClinicalTrials.gov

BF844 Safety and Pharmacokinetic Study in Healthy Volunteers

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

March 6, 2025

Study Completion Date

September 6, 2025

Conditions
Usher Syndrome Type 3
Interventions
DRUG

BF844

BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.

Trial Locations (1)

Unknown

Linear Clinical Research, Perth

All Listed Sponsors
collaborator

Usher iii Initiative

UNKNOWN

lead

EyeXCel Pty. Ltd.

OTHER

NCT06592131 - BF844 Safety and Pharmacokinetic Study in Healthy Volunteers | Biotech Hunter | Biotech Hunter